Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/10458

Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism


Thumbnail

See/Open:
 Clinical_Ruiz_THO_2018.pdf
278,63 kB
Adobe PDF
Title: Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism
Authors : Ruiz Artacho, Pedro
Trujillo Santos, Javier
López Jiménez, Luciano
Font Puig, Carme
Díaz Pedroche, María del Carmen
Sánchez Muñoz-Torrero, Juan Francisco
Peris Sifre, María Luisa
Skride, Andris
Maestre Peiró, Ana
Monreal Bosch, Manuel
Keywords: Pulmones - Cáncer - Tratamiento.Lungs - Cancer - Treatment.Anticoagulantes - Uso terapéutico.Cardiovascular system - Diseases - Treatment.Anticoagulants (Medicine) - Therapeutic use.Aparato circulatorio - Enfermedades - Tratamiento.
Publisher: Georg Thieme
Citation: Ruiz Artacho, P., Trujillo-Santos, J., López-Jiménez, L., Font, C., Díaz-Pedroche, MC., Sánchez Muñoz-Torrero, JF. et al. (2018). Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism. TH Open, vol. 2, n. 2, pp. e210-e217. DOI: https://doi.org/10.1055/s-0038-1656542
Abstract: Background: The natural history of patients with lung cancer and venous thromboembolism (VTE) has not been consistently evaluated. Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to assess the clinical characteristics, time course, and outcomes during anticoagulation of lung cancer patients with acute, symptomatic VTE. Results: As of May 2017, a total of 1,725 patients were recruited: 1,208 (70%) presented with pulmonary embolism (PE) and 517 with deep vein thrombosis (DVT). Overall, 865 patients (50%) were diagnosed with cancer <3 months before, 1,270 (74%) had metastases, and 1,250 (72%) had no additional risk factors for VTE. During anticoagulation (median, 93 days), 166 patients had symptomatic VTE recurrences (recurrent DVT: 86, PE: 80), 63 had major bleeding (intracranial 11), and 870 died. The recurrence rate was twofold higher than the major bleeding rate during the first month, and over threefold higher beyond the first month. Fifty-seven patients died of PE and 15 died of bleeding. Most fatal PEs (84%) and most fatal bleeds (67%) occurred within the firstmonth of therapy. Nine patients with fatal PE (16%) died within the first 24 hours. Of 72 patients dying of PE or bleeding, 15 (21%) had no metastases and 29 (40%) had the VTE shortly after surgery or immobility. Conclusion: Active surveillance on early signs and/or symptoms of VTE in patients with recently diagnosed lung cancer and prescription of prophylaxis in those undergoing surgery or during periods of immobilizationmight likely help prevent VTE better, detect it earlier, and treat it more efficiently.
URI: http://hdl.handle.net/10637/10458
Rights : http://creativecommons.org/licenses/by/4.0/deed.es
ISSN: 2512-9465.
Issue Date: 1-May-2018
Center : Universidad Cardenal Herrera-CEU
Appears in Collections:Dpto. Medicina y Cirugía





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.